[Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].

@article{Avril1990TreatmentOM,
  title={[Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].},
  author={M. F. Avril and Karine Beerblock and Brigitte Dr{\'e}no and Mich{\`e}le Delaunay and Jean Jacques Bonerandi and Jean Guillaume and Pierre Souteyrand and Bernard Kalis and Jacqueline Chevrant-Breton and J M Verret},
  journal={Bulletin du cancer},
  year={1990},
  volume={77 12},
  pages={1183-91}
}
Fifty patients suffering from histologically proven metastatic melanoma were treated with a combination of DTIC (400 mg/m2 i.v. every 28 days) and recombinant alpha 2A interferon (Roferon-A) 10 x 10(6) U/m2 daily, administered intramuscularly or subcutaneously for 2 months followed by 7 x 10(6) U/m2 3 times a week. Treatment was carried out for a period of… CONTINUE READING